NZ205341A - 37 residue influenza virus peptide and vaccines - Google Patents

37 residue influenza virus peptide and vaccines

Info

Publication number
NZ205341A
NZ205341A NZ205341A NZ20534183A NZ205341A NZ 205341 A NZ205341 A NZ 205341A NZ 205341 A NZ205341 A NZ 205341A NZ 20534183 A NZ20534183 A NZ 20534183A NZ 205341 A NZ205341 A NZ 205341A
Authority
NZ
New Zealand
Prior art keywords
vaccines
residue
influenza virus
virus peptide
peptide
Prior art date
Application number
NZ205341A
Other languages
English (en)
Inventor
N Green
S Alexander
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Priority to NZ22061183A priority Critical patent/NZ220611A/xx
Publication of NZ205341A publication Critical patent/NZ205341A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ205341A 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines NZ205341A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ22061183A NZ220611A (en) 1982-08-23 1983-08-22 30 residue influenza virus peptide, vaccines and antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41045582A 1982-08-23 1982-08-23

Publications (1)

Publication Number Publication Date
NZ205341A true NZ205341A (en) 1988-07-28

Family

ID=23624803

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines

Country Status (16)

Country Link
EP (1) EP0116629A4 (forum.php)
JP (1) JPS59501714A (forum.php)
KR (1) KR840006198A (forum.php)
AU (1) AU570929B2 (forum.php)
DK (1) DK203684A (forum.php)
ES (1) ES8505819A1 (forum.php)
FI (1) FI841583A0 (forum.php)
GR (1) GR78931B (forum.php)
IL (1) IL69556A (forum.php)
IT (1) IT1168636B (forum.php)
NO (1) NO161002C (forum.php)
NZ (2) NZ205341A (forum.php)
PH (1) PH18872A (forum.php)
PT (1) PT77230B (forum.php)
WO (1) WO1984000687A1 (forum.php)
ZA (1) ZA836080B (forum.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (es) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
KR910700259A (ko) * 1989-01-12 1991-03-14 리차드 이. 림바크 T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
EP0621339B1 (en) * 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US20080014205A1 (en) * 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
US8975378B2 (en) 2008-12-25 2015-03-10 Osaka University Human anti-human influenza virus antibody
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom

Also Published As

Publication number Publication date
NO841540L (no) 1984-04-17
IT8348868A0 (it) 1983-08-22
DK203684D0 (da) 1984-04-18
EP0116629A1 (en) 1984-08-29
IL69556A (en) 1988-05-31
GR78931B (forum.php) 1984-10-02
IT1168636B (it) 1987-05-20
PT77230B (en) 1986-02-04
DK203684A (da) 1984-04-18
FI841583A7 (fi) 1984-04-19
EP0116629A4 (en) 1987-06-29
AU1947183A (en) 1984-03-07
PH18872A (en) 1985-10-21
NZ220612A (en) 1988-07-28
IL69556A0 (en) 1983-11-30
PT77230A (en) 1983-09-01
NO161002C (no) 1989-06-21
WO1984000687A1 (en) 1984-03-01
ZA836080B (en) 1984-04-25
FI841583L (fi) 1984-04-19
NO161002B (no) 1989-03-13
ES525088A0 (es) 1985-06-16
ES8505819A1 (es) 1985-06-16
AU570929B2 (en) 1988-03-31
JPS59501714A (ja) 1984-10-11
KR840006198A (ko) 1984-11-22
FI841583A0 (fi) 1984-04-19

Similar Documents

Publication Publication Date Title
NZ220612A (en) 11 residue influenza virus peptide and vaccines
GB2181435B (en) Recombinant lav/htlv virus and vaccines
IL61904A (en) Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
NZ220365A (en) Antiviral peptides and pharmaceutical compositions
GB2212511B (en) Hepatitis c virus
DE3361516D1 (en) Cyanacyl amide derivatives and preparation thereof
IL80895A0 (en) Material and methods for herpes simplex virus vaccination and diagnosis based on gd-2 glycoprotein
IL64847A (en) Immunomodulating phosphorylsubstituted muramylpeptide analogues and pharmaceutical compositions containing them
AU1255383A (en) Foot and mouth disease viral antigenic peptides
ZA864879B (en) Vaccines and diagnostics derived from boving diarrhoea virus
EP0210931A3 (en) Vaccine against varicella-zoster virus
GB2130090B (en) Pharmaceutical preparations and compositions
GB8324970D0 (en) Tripeptide and tetrapeptide alkylamides
NZ221374A (en) Recombinant interferon and compositions containing it
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
IL89118A0 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
GB8918689D0 (en) 25/15 vaccine
ZA874847B (en) Oncornavirus vaccines
ZA903142B (en) Canine corona virus vaccine
IL79740A0 (en) Hepatitis vaccine
IL79880A0 (en) Recombinant virus
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
ZA837058B (en) Peptide and use thereof